Enara Bio in their own words...
Enara Bio™ (formerly known as Ervaxx) is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Our current focus is the development of novel T-cell therapies based on complementary and proprietary insights from interrogating the immune synapse from both angles – on the tumor side, a growing set of novel tumor-specific targets; and on the T-cell side, a set of robust T-cell receptors (TCRs) with potent tumoricidal activity.
Enara Bio was founded in 2016 and has been well funded to invest in the build out and growth of our proprietary discovery platform and our fantastic team. The company has offices in London, UK and laboratories in Oxford, UK.
